Physician Assistant Program year 2022 Reported 2021–2022 Source: CMS Open Payments, 2026 publication

Iman Eltay

Physician Assistant Mason, OH Physician Assistant

NPI 1477506947 CMS profile 11141172

8350 Arbor Square Dr, Mason, OH 45040

Open in the dashboard

General payments

$2,096

120 records reported · program years 2021–2022

Research payments

$0

Paid to them · None reported · program years 2021–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Iman Eltay of Mason, OH is reported in the CMS Open Payments database as having received $2,096 across 120 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $1,155 69
2021 General $941 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Iman Eltay
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Iman Eltay were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Iman Eltay Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $941 $132 $37–$438 $132
2022 $1,155 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2022
  1. Amgen Inc. $321 10 payments
  2. Lilly USA, LLC $264 23 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $255 9 payments
  4. AbbVie, Inc. $212 15 payments
  5. Novo Nordisk Inc $158 10 payments
  6. Almatica Pharma LLC $133 6 payments
  7. GlaxoSmithKline, LLC. $123 7 payments
  8. Amarin Pharma Inc. $100 5 payments
  9. Abbott Laboratories $79 4 payments
  10. Janssen Pharmaceuticals, Inc $62 5 payments
  11. Other $388 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2022
  1. Food and Beverage $2,096 120 payments
Products named General payments · program years 2021–2022
  1. Otezla $254 4 payments
  2. JARDIANCE Diabetes $229 7 payments
  3. GRALISE $133 6 payments
  4. TRULICITY $123 9 payments
  5. TRELEGY ELLIPTA $108 6 payments
  6. Vascepa $100 5 payments
  7. JARDIANCE Diabetes $89 11 payments
  8. Ozempic $80 5 payments
  9. VRAYLAR $79 4 payments
  10. FreeStyle Libre 2 $79 4 payments
  11. Other $1,111 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

470

Median for Physician Assistant: 241

Drug cost

$3,373

Median for Physician Assistant: $4,110

Branded share of claims

22.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Azelastine Hcl Generic 38 $580
Albuterol Sulfate Hfa Albuterol Sulfate Brand 26 $571
Methylprednisolone Generic 81 $425
Cefuroxime Cefuroxime Axetil Brand 28 $389
Azithromycin Generic 83 $247
Doxycycline Hyclate Generic 28 $234
Oseltamivir Phosphate Generic 14 $203
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 11 $133
Mupirocin Generic 14 $111
Cephalexin Generic 29 $95

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$19,651

Of which drugs: $115

Medicare patients

274

Average age 74

Services billed

572

175 women, 99 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 49%
Ischemic heart disease 26%
Diabetes 24%
Depression 19%
Osteoporosis 18%
Chronic kidney disease 17%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

120 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record